Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00697450

NN304-3560

Details and patient eligibility

About

This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins

Enrollment: 206 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• Current treatment with insulin NPH or glargine
• The selection of the subjects will be at the discretion of the individual physician

Exclusion criteria

• Current treatment with insulin detemir
• Previous enrolment in this study
• Hypersensitivity to insulin detemir or to any of the excipients.
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months

Trial design

206 participants in 1 patient group

All participants

Treatment:

Drug: insulin detemir